Catabasis Pharmaceuticals Inc: Rare disease pipeline; Top-line results expected 2020 from ongoing Ph 3 trial of Edasalonexent in in DMD regardless of mutation type. North Star Ambulatory Assessment as primary endpt based on Ph 2 results and FDA input.
Based in...
US - New England
Clinical Stage
Phase III
Disease Space
Rare Disease
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Platform Technology, Small Molecule
One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, MA 02139
United States

Top 10 Holders of Catabasis Pharmaceuticals Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Federated Global Investment Management Corp. 26.02 3,047,800 21.33 13F 6/30/20
Altium Capital Management LP 4.85 925,000 6.48 Stakes 12/31/19
The Vanguard Group, Inc. 6.42 754,668 5.28 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 6.06 710,048 4.97 13F 6/30/20
Corriente Advisors LLC 3.23 617,084 4.32 Stakes 12/31/19
BlackRock Fund Advisors 4.99 584,915 4.09 13F 6/30/20
BlackRock Institutional Trust Co. NA 3.38 395,614 2.77 13F 6/30/20
Stonepine Capital Management LLC 2.04 390,000 2.73 Stakes 12/31/19
Samsara Biocapital LLC 2.56 300,000 2.10 13F 6/30/20
SV Health Investors LLC 2.44 285,765 2.00 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.